The C-reactive protein–ALB ratio before treatment can be used as a potential prognostic biomarker in patients with head and neck cancer, esophageal cancer, and bile duct cancer; an elevated C-reactive protein–ALB ratio predicts a poorer prognosis [25,26,27]. The gene discussed is ALB; the disease is head and neck cancer.